Scope and Claims Analysis for US Drug Patent 10,525,045 (Fabry disease; 1-deoxygalactonojirimycin every-other-day oral exposure targets)
US Patent 10,525,045 is a US-method-of-treatment patent for Fabry disease that tightly links (i) the active ingredient, (ii) dosing frequency, and (iii) specific oral PK exposure “bioequivalent” targets (Cmax, Tmax, and/or half-life) to a therapeutic method. The claim set is structured to preserve enforceable coverage across generic/bioequivalent variants by using “bioequivalent to about” and, in dependent form, tighter “within 20%” thresholds, while still requiring oral dosing and α-galactosidase A activity enhancement when those limitations are invoked by the dependent claims.
Bottom line: the estate’s practical bite is on competitors attempting “every other day” oral 1-deoxygalactonojirimycin regimens that aim for oral exposure comparable to the recited Cmax ≈ 9 µM and Tmax ≈ 3 hours, and/or half-life ≈ 3 hours. Any commercial program that shifts dosing cadence (daily, twice daily, weekly) or materially alters exposure windows (lower Cmax, delayed Tmax, longer half-life) is pushed outside core claim scope. Programs that only substitute a different route (IV) or avoid the stated PK targets are also exposed.
What is US Patent 10,525,045 and what does it cover for Fabry disease?
Direct coverage (independent claims):
- The claimed invention is a method for treating Fabry disease by administering 1-deoxygalactonojirimycin (DGJ) or a salt.
- The method is limited to patients “in need thereof.”
- Dosing frequency is every other day.
- The key enforcement hook is the PK-performance requirement: the therapeutic regimen produces one or more exposure properties that are bioequivalent to specified values.
Claim 1: “bioequivalent to about” PK targets tied to every-other-day dosing
Claim 1 requires:
- DGJ or a salt.
- Every other day dosing.
- Oral? Not required in claim 1 (that appears in dependent claim 2).
- One or more of the following must be met:
- Cmax bioequivalent to about 9 µM
- Tmax bioequivalent to about 3 hours
- t1/2 bioequivalent to about 3 hours
Claim 1 is therefore broad on which PK dimension is met: a product could meet Cmax but not Tmax, still satisfying the “one or more” structure.
Claim 10: tighter “within 20%” PK thresholds (independent claim)
Claim 10 similarly requires:
- DGJ or a salt administered every other day.
- One or more exposure properties met:
- Cmax within 20% of 9 µM
- Tmax within 20% of 3 hours
- t1/2 within 20% of 3 hours
Claim 10 is narrower than claim 1 in that it replaces “bioequivalent” language with explicit ±20% windows, but it is still broad in which parameter is satisfied (“one or more”).
Dependent claims: route, dosage forms, mechanism enhancement, and sex stratification
Dependent claims narrow the method in discrete dimensions:
- Claim 2: oral dosage form required.
- Claim 3: oral dosage form can be tablet, capsule, or solution.
- Claim 4: DGJ enhances α-galactosidase A activity (mechanism/PD linkage).
- Claims 5 and 6: male or female patient limitations.
- Claims 7–9: variants of claim 1 where the method provides a bioequivalent value for the specific PK endpoint (Cmax, Tmax, or t1/2 respectively).
- Claims 11–13: route and dosage-form requirements mirrored for the claim 10 structure; claim 13 ties to α-galactosidase A activity.
- Claims 14–15: male or female mirrored for claim 10.
- Claims 16–18: explicit “within 20%” specificity for Cmax, Tmax, t1/2.
Practical note on claim architecture: the independent claims do not require oral dosing, but once you are in dependent-claim territory, oral route becomes mandatory. In litigation, this structure often creates a two-track position: the patent can attack non-oral dosing under claim 1/10 only if a court reads oral requirements only into dependent claims (as written), and it can enforce route-limited versions under claims 2/3/11/12.
How do the PK “bioequivalent” and “within 20%” limitations affect claim scope?
“Bioequivalent to about” (Claim 1) is inherently interpretive
Claim 1 uses “bioequivalent to about” for Cmax, Tmax, and/or half-life. That phrasing tends to invite argument about:
- what “about” means (central tendency around 9 µM, 3 hours, etc.),
- what “bioequivalent” means in the patent’s context (often tied to conventional regulatory/bioequivalence concepts, but not specified in the claim text).
The claim is still anchored by fixed numeric targets: 9 µM for Cmax; 3 hours for Tmax and t1/2.
“Within 20%” (Claim 10) converts interpretive risk into a clear numeric window
Claim 10 uses explicit windows:
- Cmax in the range 0.8×9 to 1.2×9 µM
- Tmax in the range 0.8×3 to 1.2×3 hours
- t1/2 in the range 0.8×3 to 1.2×3 hours
The “one or more” framing means even if only one of these endpoints is within range, claim 10 can still be satisfied.
Litigation consequence: claim coverage is triggered by observed clinical PK
Because the claim is method-of-treatment tied to achieved plasma exposure after dosing, infringement analysis typically uses:
- clinical PK studies (including crossover designs),
- observed plasma concentration-time profiles,
- mapping to the defined Cmax/Tmax/t1/2 metrics.
This makes PK strategy a direct IP risk lever for any competitor.
What formulations and dosage forms are protected by US 10,525,045?
US 10,525,045 is primarily a method patent, not a composition patent. But it includes route/dosage form dependent claims that matter in product design and marketing.
Oral dosage forms explicitly covered (dependent claims)
- Claim 2: oral dosage form required.
- Claim 3: oral dosage form comprises tablet, capsule, or solution.
If a competitor introduces a formulation marketed for oral use, the risk shifts toward dependent-claim infringement, assuming other limitations are met (every-other-day dosing and PK targets in claim 10’s “within 20%” track or claim 1’s “bioequivalent” track).
Salt forms are within scope
All methods require “1-deoxygalactonojirimycin or a salt thereof.” That language is broad enough to capture multiple pharmaceutically acceptable salt forms used for oral delivery.
What patient population limitations are included in the claims?
Claims 5, 6, 14, and 15 add:
- male patients (claims 5 and 14)
- female patients (claims 6 and 15)
These do not narrow the overall estate in a meaningful “who can be treated” sense because the male/female set appears to cover both sexes via two dependent claims under each independent claim family. They may still be relevant for infringement proofs that rely on sex-stratified PK/PD datasets, but as written they do not exclude either sex.
What is the therapeutic mechanism limitation and why does it matter?
Dependent claim 4 and claim 13 require that the DGJ or salt enhances α-galactosidase A activity.
This is a PD linkage that can become an infringement battleground:
- If a competitor argues the exposure targets are met but PD effects are not “enhanced” in the requisite direction or magnitude, they may try to avoid dependent-claim infringement.
- Claim 1/10 do not require the α-galactosidase A enhancement, so the mechanism limitation is not a prerequisite for independent-claim infringement.
Net effect: α-galactosidase A enhancement is an additional layer of enforceability for competitors who are close on dosing and PK but want to avoid PD-based arguments under the dependent claims.
What is the effective “dosing strategy” that the patent claims are designed to capture?
The estate is designed around a specific clinical regimen signature:
- Every other day administration of DGJ (or salt).
- Oral route when dependent claims are asserted.
- Achievement of plasma exposure consistent with:
- Cmax ≈ 9 µM
- Tmax ≈ 3 hours
- t1/2 ≈ 3 hours
Key design around: change one axis and you may exit scope
For a competitor, the easiest “design around” levers based on claim text are:
- Change dosing frequency away from every other day.
- Shift oral PK so Cmax, Tmax, or t1/2 is not bioequivalent/within the specified windows.
- Avoid oral route (to escape dependent oral/dosage-form claims), while noting independent claims 1/10 do not expressly require oral route.
- Change PD relationship so α-galactosidase A activity is not “enhanced” as required by dependent claims (if litigated under those claims).
What generic entry risks exist for 1-deoxygalactonojirimycin in Fabry disease under this patent?
Risk for “same regimen, bioequivalent exposure” products
If a generic seeks to match:
- every-other-day dosing,
- oral tablet/capsule/solution delivery,
- and PK that lands near Cmax ~9 µM and Tmax ~3 hours,
then the product directly maps to the numeric targets in both independent-claim families.
Risk increases when the program targets bioequivalence by design
Bioequivalence studies generally aim to match Cmax and AUC, while Tmax and half-life can shift with formulation and food effects. Because this patent includes Tmax and t1/2 targets explicitly, a competitor cannot rely on “AUC/Bioequivence” alone as a shield.
Settlement leverage based on PK endpoints
Because the enforceability is tied to measurable PK metrics, parties can structure settlements around:
- agreed dosing schedules,
- agreed exposure profiles,
- label restrictions on regimen timing/frequency.
This tends to make the patent a strong negotiation tool in licensing contexts where competitors want to launch with a specific regimen.
How strong is the claim estate likely to be on scope and infringement burden?
Strengths in enforceability from claim wording
- Clear numeric anchors for Cmax, Tmax, and t1/2 (especially claim 10).
- Regimen specificity (every other day).
- Multiple overlapping claim layers:
- independent claims 1 and 10,
- dependent claim families that tighten the PK endpoint,
- route and dosage-form limitations (oral tablet/capsule/solution),
- PD enhancement (α-galactosidase A activity).
Potential friction points for challengers
- “Bioequivalent to about” in claim 1 may require expert debate, but the numeric “about” targets still constrain outcomes.
- “One or more” structure means plaintiffs can focus on whichever PK metric is easiest to prove in the accused product.
Net: the claim set is built to reduce easy escape routes while preserving multiple infringement theories tied to measurable outcomes.
What does the patent landscape look like beyond US 10,525,045?
The provided input contains only the claims of US 10,525,045, not:
- priority numbers,
- continuation/divisional relationships,
- family members in other jurisdictions,
- listed Orange Book products tied to the patent,
- or litigation/public docket outcomes.
Accordingly, a full multi-patent landscape cannot be produced from the provided data.
Key Takeaways
- US Patent 10,525,045 protects Fabry disease treatment methods using 1-deoxygalactonojirimycin (or salts) administered every other day with specified oral plasma exposure targets.
- Claim 1 requires PK “bioequivalent” to about Cmax 9 µM and/or Tmax 3 hours and/or t1/2 3 hours; claim 10 tightens this to within 20% windows.
- Dependent claims add oral delivery (tablet, capsule, or solution) and α-galactosidase A activity enhancement, creating layered infringement theories.
- For generic or follow-on development, the core entry risk is matching both regimen frequency and PK exposure profile, including Tmax and half-life, not just Cmax/AUC.
FAQs
1) Can a product infringe if it matches Cmax but not Tmax or half-life?
Yes. Both independent claims use “one or more” of the PK endpoints, so meeting only Cmax (within the defined “bioequivalent” or “within 20%” frameworks) can satisfy the independent limitation.
2) Does the patent require oral dosing?
No for independent claims 1 and 10. Oral route is required in dependent claims 2 and 11, with additional dosage form limits in claims 3 and 12.
3) Are salt forms covered?
Yes. Each method requires administering 1-deoxygalactonojirimycin or a salt thereof.
4) What happens if dosing frequency is changed to daily or weekly?
Changing the cadence away from every other day is a direct departure from the central regimen limitation in the independent claims and would typically avoid the core method claim coverage.
5) What endpoint can plaintiffs focus on if PK data are incomplete?
Because the independent claims allow satisfaction by “one or more” endpoints, plaintiffs can target the PK metric with the strongest match to the defined targets.
References
No sources were provided in the prompt beyond the claim text; no additional citations can be generated from the given information.
